Study S001830

Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06976853
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: RECRUITING
Enrollment: 60
Start: 2025-05-13
Primary completion: 2028-05
Lead sponsor: Washington University School of Medicine
Conditions: Crohn Disease (CD)
Interventions: DRUG:Tirzepatide; DRUG:Standard of care treatment
Results posted: FALSE

Registered primary outcomes

Proportion and number of participants who have treatment emergent adverse events, serious adverse events, discontinuation of study intervention due to adverse events and injection-site reactions by CTCAE v4.0 [From enrollment to the end of treatment at month 7]
Number of participants who achieve various doses of Tirzepatide at increments of 2.5 mg, up to 15 mg [From enrollment to the end of treatment at month 7]
Proportion and number of participants with endoscopic remission as defined by SES-CD < 4 with no ulcer subscore >1. [From enrollment to the end of treatment at month 7]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.